"Key Driver for Blockbuster Drug Success"

On July 27, HK Innoen announced that it has added "prevention of peptic ulcers associated with nonsteroidal anti-inflammatory drugs (NSAIDs)" as the sixth indication for its new gastroesophageal reflux disease drug, K-Cab (active ingredient: tegoprazan).


K-Cab now has a total of six approved indications: treatment of erosive gastroesophageal reflux disease, treatment of non-erosive gastroesophageal reflux disease, treatment of gastric ulcers, combination antibiotic therapy for Helicobacter pylori eradication in patients with peptic ulcers or chronic atrophic gastritis, maintenance therapy after treatment of erosive gastroesophageal reflux disease, and prevention of peptic ulcer (gastric and duodenal ulcer) associated with NSAID use. This is the highest number of indications among P-CAB class therapies in Korea.


HK Innoen Esophageal Reflux Disease New Drug K-Cab Series. HK Innoen

HK Innoen Esophageal Reflux Disease New Drug K-Cab Series. HK Innoen

View original image

Due to the rapid increase in chronic pain patients driven by population aging, the demand for NSAIDs is on the rise. K-Cab is expected to provide a new option in the NSAID combination therapy market, which has previously been dominated by conventional PPI class drugs.



Dalwon Kwak, CEO of HK Innoen, stated, "Managing gastrointestinal adverse effects caused by long-term use of anti-inflammatory analgesics is an unmet global need. The robust clinical data accumulated through the addition of this new indication is expected to serve as a key driver for K-Cab to become a blockbuster drug not only in the domestic market but also in the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing